A Novel Description of Antithrombin Deficiency in Hospitalized COVID-19 Patients
Objective
Antithrombin (AT) helps reduce inflammation and blood clotting. We wanted to find out how common AT deficiency is in COVID-19 patients and if adding AT could help with blood clotting issues in these patients.
Patients and Methods
This study involved a randomized control trial. Patients with low AT levels (<100%) were divided into two groups: one received standard care, and the other received standard care plus AT every 48 hours. We also had a reference group with normal AT levels (>100%).
Results
A total of 531 patients were evaluated, but only 50 completed the study. Most patients (76%) had AT levels below 100%. The changes in blood clotting scores and hospital stays were similar across all groups. Mortality rates were also comparable. There was one bleeding incident in a patient with normal AT levels, but none in those receiving AT treatment. No adverse effects from AT were reported.
Conclusions
COVID-19 is linked to AT deficiency in some patients. Adding AT did not lead to bleeding issues or significant differences in hospital stay or mortality rates. Further research is needed to explore higher doses of AT in higher-risk patients.
Clinical Trials Information
ClinicalTrials.gov: NCT04899232
Value of Clinical Trials
Clinical trials are essential for creating safe and effective treatments. Our AI-driven platform, DocSym, combines clinical standards and research into one easy-to-use resource for healthcare providers.
Practical Solutions for Healthcare
In today’s healthcare landscape, efficiency is key. Our mobile apps assist with scheduling, treatment monitoring, and telemedicine, simplifying patient care management.
Enhancing Patient Outcomes
By integrating AI, clinics can improve workflows, enhance patient outcomes, and reduce paperwork. Discover how we can support your practice at aidevmd.com.
